Hence, TP53RK is emerging as a novel oncogene protein and therapeutic target against these cancers.[11, 36, 37, 38] Meanwhile, as an important component of the EKC/KEOPS complex that plays a central role in the synthesis of an essential tRNA modification, mutations of TP53RK cause GAMOS.[9] Our current research showed that TP53RK also functions to promote CKD kidney fibrosis and the profibrotic effect of TP53RK may rely on its regulation on Birc5, rather than p53. The gene discussed is TP53; the disease is chronic kidney disease.